Page 54 - Practice Guidelines News Today

ABBVie , today announced extended long-term data from the Phase 3 RESONATE-2 study evaluating single-agent IMBRUVICA versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma . 1 These data will be presented on June 4 th during the 2021 American Society of Clinical Oncology Annual Meeting . Additionally, new data will be presented during the ...

/PRNewswire/ -- AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent...

June 3, 2021 Results show that first-of-its-kind device has a sustained treatment effect and a positive impact on quality of life Amsterdam, the Netherlands - Royal Philipsconference

June 3, 2021 has a Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial. The data show the Philips Tack Endovascular System (4F), a first-of-its kind dissection repair device, provides a sustained treatment effect and positive impact on quality of life for Peripheral Artery Disease (PAD) and Critical Limb Ische...

Royal Philips Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System June 3, 2021 has a Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack ...

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the publication of a new resource to help employers make the best decisions...

In CheckMate -577, Opdivo 1 Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer 1 PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic...

(2) - ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) in onc...

NCCN Releases New Patient Guidelines on Anemia and Neutropenia NCCN.org/patientguidelines (NCCN : Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and endorsed by The Leukemia and Lymphoma Society (LLS). The free information source is designed to help people living with cancer and caregivers recognize symptoms of blood cell deficiencies caused by cancer or chemotherapy-and increase engagement with their oncology care team about management and support. C...

Washington is sending help to reduce opioid deaths across NY, nation (Guest opinion) Updated 4:11 PM; Today 2:16 PM This July 23, 2018 file photo shows packets of buprenorphine, a drug which controls heroin and opioid cravings, in Greenfield, Mass. The U.S. government is easing requirements that made it difficult for doctors to treat opioid addiction using the medication. New guidelines announced Tuesday, April 27, 2021, mean doctors will no longer need eight hours of training to prescribe bu...